{"id":11169,"date":"2012-08-15T00:00:00","date_gmt":"2012-08-15T00:00:00","guid":{"rendered":"https:\/\/www.cancerresearch.org\/media-room\/pancreatic-cancer-immunotherapy-clinical-trial-launches-at-upenn\/"},"modified":"2022-07-13T05:08:54","modified_gmt":"2022-07-13T05:08:54","slug":"carl-june-pancreatic-cancer-trial","status":"publish","type":"cri_news","link":"https:\/\/www.cancerresearch.org\/es\/media-room\/carl-june-pancreatic-cancer-trial","title":{"rendered":"Pancreatic Cancer Immunotherapy Clinical Trial Launches at UPENN"},"content":{"rendered":"\n

The Lustgarten Foundation, the nation\u2019s largest private foundation dedicated solely to funding pancreatic cancer research, and the Cancer Research Institute (CRI), a nonprofit organization devoted to transforming cancer patient care through the discovery and development of immune system-based cancer therapies, are co-sponsoring a new approach to the treatment of pancreatic cancer. A new clinical trial led by Dr. Carl June and Dr. Gregory Beatty at the Perelman School of Medicine at the University of Pennsylvania will focus on altering and training a patient\u2019s immune system to target and eliminate cancer cells.<\/p>\n\n\n\n

As part of the clinical trial, each participating patient will have a type of immune cell called T cells removed from their blood. Using a revolutionary new approach, the T cells are then genetically modified to express protein complexes known as chimeric antigen receptors (CARs), which act as a tool to help the reprogrammed T cells recognize and destroy pancreatic cancer cells. The altered T cells are put back into the patient so his or her immune system can begin fighting the pancreatic cancer.<\/p>\n\n\n\n

\u201cThink of it like altering the gene sequence of these T cells so that they become trained assassins working for an individual\u2019s immune system, focused exclusively on finding and killing the cancer cells,\u201d said Dr. Carl June, professor of Pathology and Laboratory Medicine, the Perelman School of Medicine at the University of Pennsylvania. \u201cThis research has shown very promising results in other cancers we\u2019ve applied it to, so we\u2019re grateful to The Lustgarten Foundation and the Cancer Research Institute for their support, which will enable us to continue this important work for pancreatic cancer.\u201d<\/p>\n\n\n\n

\u201cPancreatic cancer is the most lethal of all cancers. That\u2019s why this new research is so promising and that\u2019s why we\u2019re pleased to partner with the Cancer Research Institute and the University of Pennsylvania to conduct this clinical trial,\u201d said Kerri Kaplan, executive director, The Lustgarten Foundation. \u201cWe remain dedicated to advancing pancreatic cancer research by funding promising studies like this one, so we can find better treatments and ultimately, a cure for pancreatic cancer.\u201d<\/p>\n\n\n\n

\u201cWe are proud to collaborate with The Lustgarten Foundation and the University of Pennsylvania on this new approach to treating pancreatic cancer with the immune system,\u201d said Jill O\u2019Donnell-Tormey, PhD, chief executive officer and director of scientific affairs, the Cancer Research Institute. \u201cThis powerful partnership leverages our combined expertise in cancer immunotherapy, pancreatic cancer, and treating cancer patients to bring new hope to people impacted by this deadly disease.\u201d<\/p>\n\n\n\n

The collaborative study grew out of a daylong think tank organized by the Cancer Research Institute and The Lustgarten Foundation, whereby a research map for immunotherapy for pancreatic cancer was identified and prioritized.<\/p>\n\n\n\n

This trial is expected to open this fall and continue throughout the next year.<\/p>\n\n\n\n\n\n

Media Contacts<\/strong><\/p>\n\n\n\n

Martin Blair, Lustgarten Foundation
212-576-270 or mblair@goodmanmedia.com<\/a><\/p>\n\n\n\n

Brian Brewer, Cancer Research Institute
212-688-7515, ext. 242 or bbrewer@cancerresearch.org<\/a><\/p>\n\n\n\n

About The Lustgarten Foundation<\/strong>
The Lustgarten Foundation is America\u2019s largest private foundation dedicated solely to funding pancreatic cancer research. Based in Bethpage, New York, the Foundation supports research to find a cure for pancreatic cancer, facilitates dialogue within the medical and scientific community, and educates the public about the disease through awareness campaigns and fundraising events. The Foundation has provided millions of research dollars and assembled the best scientific minds with the hope that one day, a cure can be found. And because Cablevision Systems Corporation, a leading media and telecommunications company, underwrites all of The Lustgarten Foundation\u2019s administrative costs, 100 percent of every dollar donated to the Foundation goes directly to pancreatic cancer research. Learn more at www.lustgarten.org<\/a>.<\/p>\n\n\n\n

About Perelman School of Medicine at the University of Pennsylvania<\/strong>
The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report’s<\/em> survey of research-oriented medical schools and is consistently among the nation’s top three recipients of federal funding from the National Institutes of Health. Penn’s physicians and scientists focus on research that utilizes an interdisciplinary approach to understand the fundamental mechanisms of disease, leading to new strategies for treatments and cures. In addition, faculty from 23 institutes and centers at Penn Medicine work together with their counterparts from the 11 other schools at the University of Pennsylvania to collaborate in such disparate areas as aging, neuroscience, and the impact of health care policy.<\/p>\n","protected":false},"excerpt":{"rendered":"

A new clinical trial for pancreatic cancer immunotherapy funded by the Cancer Research Institute and the Lustgarten Foundation will open at the University of Pennsylvania under the supervision of Dr. Carl H. June.<\/p>\n","protected":false},"featured_media":934,"template":"","tags":[32,98,109],"resource_cancer_types":[],"resource_patient_age":[],"resource_cancer_stage":[],"resource_treatment_type":[],"resource_treatment_status":[],"class_list":["post-11169","cri_news","type-cri_news","status-publish","has-post-thumbnail","hentry","tag-clinical-trials","tag-pancreatic-cancer","tag-research"],"acf":[],"yoast_head":"\nPancreatic Cancer Immunotherapy Clinical Trial Launches at UPENN - Cancer Research Institute<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cancerresearch.org\/media-room\/carl-june-pancreatic-cancer-trial\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pancreatic Cancer Immunotherapy Clinical Trial Launches at UPENN - Cancer Research Institute\" \/>\n<meta property=\"og:description\" content=\"A new clinical trial for pancreatic cancer immunotherapy funded by the Cancer Research Institute and the Lustgarten Foundation will open at the University of Pennsylvania under the supervision of Dr. Carl H. June.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cancerresearch.org\/media-room\/carl-june-pancreatic-cancer-trial\" \/>\n<meta property=\"og:site_name\" content=\"Cancer Research Institute\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-13T05:08:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/6aa8e0f1-dcd2-4c04-88bc-88332f59e608.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"206\" \/>\n\t<meta property=\"og:image:height\" content=\"136\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/carl-june-pancreatic-cancer-trial\",\"url\":\"https:\/\/www.cancerresearch.org\/media-room\/carl-june-pancreatic-cancer-trial\",\"name\":\"Pancreatic Cancer Immunotherapy Clinical Trial Launches at UPENN - Cancer Research Institute\",\"isPartOf\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/carl-june-pancreatic-cancer-trial#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/carl-june-pancreatic-cancer-trial#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/6aa8e0f1-dcd2-4c04-88bc-88332f59e608.jpg\",\"datePublished\":\"2012-08-15T00:00:00+00:00\",\"dateModified\":\"2022-07-13T05:08:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/carl-june-pancreatic-cancer-trial#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cancerresearch.org\/media-room\/carl-june-pancreatic-cancer-trial\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/carl-june-pancreatic-cancer-trial#primaryimage\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/6aa8e0f1-dcd2-4c04-88bc-88332f59e608.jpg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/6aa8e0f1-dcd2-4c04-88bc-88332f59e608.jpg\",\"width\":206,\"height\":136},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/carl-june-pancreatic-cancer-trial#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cancerresearch.org\/es\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Media Room Article\",\"item\":\"https:\/\/www.cancerresearch.org\/media-room\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Pancreatic Cancer Immunotherapy Clinical Trial Launches at UPENN\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cancerresearch.org\/#website\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"name\":\"Cancer Research Institute\",\"description\":\"For a World Immune to Cancer\",\"publisher\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cancerresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\",\"name\":\"Cancer Research Institute\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"width\":156,\"height\":53,\"caption\":\"Cancer Research Institute\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pancreatic Cancer Immunotherapy Clinical Trial Launches at UPENN - Cancer Research Institute","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cancerresearch.org\/media-room\/carl-june-pancreatic-cancer-trial","og_locale":"es_ES","og_type":"article","og_title":"Pancreatic Cancer Immunotherapy Clinical Trial Launches at UPENN - Cancer Research Institute","og_description":"A new clinical trial for pancreatic cancer immunotherapy funded by the Cancer Research Institute and the Lustgarten Foundation will open at the University of Pennsylvania under the supervision of Dr. Carl H. June.","og_url":"https:\/\/www.cancerresearch.org\/media-room\/carl-june-pancreatic-cancer-trial","og_site_name":"Cancer Research Institute","article_modified_time":"2022-07-13T05:08:54+00:00","og_image":[{"width":206,"height":136,"url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/6aa8e0f1-dcd2-4c04-88bc-88332f59e608.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cancerresearch.org\/media-room\/carl-june-pancreatic-cancer-trial","url":"https:\/\/www.cancerresearch.org\/media-room\/carl-june-pancreatic-cancer-trial","name":"Pancreatic Cancer Immunotherapy Clinical Trial Launches at UPENN - Cancer Research Institute","isPartOf":{"@id":"https:\/\/www.cancerresearch.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cancerresearch.org\/media-room\/carl-june-pancreatic-cancer-trial#primaryimage"},"image":{"@id":"https:\/\/www.cancerresearch.org\/media-room\/carl-june-pancreatic-cancer-trial#primaryimage"},"thumbnailUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/6aa8e0f1-dcd2-4c04-88bc-88332f59e608.jpg","datePublished":"2012-08-15T00:00:00+00:00","dateModified":"2022-07-13T05:08:54+00:00","breadcrumb":{"@id":"https:\/\/www.cancerresearch.org\/media-room\/carl-june-pancreatic-cancer-trial#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cancerresearch.org\/media-room\/carl-june-pancreatic-cancer-trial"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/media-room\/carl-june-pancreatic-cancer-trial#primaryimage","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/6aa8e0f1-dcd2-4c04-88bc-88332f59e608.jpg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/6aa8e0f1-dcd2-4c04-88bc-88332f59e608.jpg","width":206,"height":136},{"@type":"BreadcrumbList","@id":"https:\/\/www.cancerresearch.org\/media-room\/carl-june-pancreatic-cancer-trial#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cancerresearch.org\/es"},{"@type":"ListItem","position":2,"name":"Media Room Article","item":"https:\/\/www.cancerresearch.org\/media-room"},{"@type":"ListItem","position":3,"name":"Pancreatic Cancer Immunotherapy Clinical Trial Launches at UPENN"}]},{"@type":"WebSite","@id":"https:\/\/www.cancerresearch.org\/#website","url":"https:\/\/www.cancerresearch.org\/","name":"Cancer Research Institute","description":"For a World Immune to Cancer","publisher":{"@id":"https:\/\/www.cancerresearch.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cancerresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cancerresearch.org\/#organization","name":"Cancer Research Institute","url":"https:\/\/www.cancerresearch.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","width":156,"height":53,"caption":"Cancer Research Institute"},"image":{"@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_news\/11169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_news"}],"about":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/types\/cri_news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media\/934"}],"wp:attachment":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media?parent=11169"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tags?post=11169"},{"taxonomy":"resource_cancer_types","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_cancer_types?post=11169"},{"taxonomy":"resource_patient_age","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_patient_age?post=11169"},{"taxonomy":"resource_cancer_stage","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_cancer_stage?post=11169"},{"taxonomy":"resource_treatment_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_treatment_type?post=11169"},{"taxonomy":"resource_treatment_status","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_treatment_status?post=11169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}